• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    RxSight, Inc. Appoints Raymond W. Cohen to Its Board of Directors

    8/4/25 8:05:00 AM ET
    $AXNX
    $KMTS
    $NSPR
    $RXST
    Medical/Dental Instruments
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $AXNX alert in real time by email

    ALISO VIEJO, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced the appointment of Raymond W. Cohen to its Board of Directors.

    "We are thrilled to welcome Raymond W. Cohen to the RxSight Board of Directors," said J. Andy Corley, Chairman of the Board at RxSight. "Ray's extensive track record in leading and scaling medical technology companies will be invaluable as we advance our strategy and enter the next phase of growth. His insights and guidance will help us expand the reach of the RxSight® Light Adjustable Lens system, enabling more physicians and patients to benefit from truly customized vision after cataract surgery."

    Mr. Cohen, an accredited public company director and accomplished medical technology executive, has over four decades of industry experience. He was the co-founder and chief executive officer of Axonics, Inc. (NASDAQ:AXNX) a global leader in implantable neuromodulation devices that completed its initial public offering in 2018. Under his leadership, Axonics generated over $1 billion in revenue within four years of its commercial launch, became profitable, earned recognition as the fastest-growing technology company in North America and was acquired by Boston Scientific in 2024 for $3.7 billion. In March 2025, Mr. Cohen, as chairman of SoniVie, Ltd., an Israeli clinical stage company, led the sale of that company to Boston Scientific for $600 million.

    "I see tremendous potential for RxSight to get back on its growth track by strengthening its position in the premium intraocular lens market," said Raymond W. Cohen. "Over the years, RxSight has demonstrated exceptional outcomes for cataract surgery patients with its groundbreaking RxSight Light Adjustable Lens system. I look forward to collaborating with the Board and management team to support the company's mission to accelerate growth in revenue and profits."

    Cohen currently serves on the boards of several innovative healthcare companies, including Kestra Medical Technologies (NASDAQ:KMTS), where he is an independent director and chair of the compensation committee; InspireMD (NASDAQ:NSPR) as an independent director, as well as privately-held Nalu Medical as chairman, Archimedes Vascular as chairman, Tulavi Medical as vice chairman, and Spectrum Vascular as an independent director. Mr. Cohen also serves as a venture partner with Andera Partners and Sherpa Capital Partners.

    About RxSight, Inc.

    RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+®, collectively the "LAL"), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.

    Forward-Looking Statements

    This press release contains forward-looking statements, including statements regarding the anticipated contributions of Raymond W. Cohen as a member of RxSight's Board of Directors, RxSight's ability to advance its strategy, return to a growth trajectory, and accelerate revenue and profit expansion, as well as RxSight's ability to expand the reach of the RxSight® Light Adjustable Lens system and enable customized vision outcomes for more patients. These statements are based on current expectations and assumptions and involve known and unknown risks and uncertainties, many of which are beyond the company's control.

    Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those expressed or implied in these statements. Words such as "may," "will," "expect," "anticipate," "intend," "believe," "plan," "seek," "estimate," and similar expressions are intended to identify forward-looking statements. Any forward-looking information contained in this press release speaks only as of the date hereof, and RxSight undertakes no obligation to update or revise such statements to reflect new information, future events, or otherwise, except as required by law.

    Company Contact:

    Shelley B. Thunen

    Chief Financial Officer

    [email protected]

    Investor Relations Contact:

    Oliver Moravcevic

    VP, Investor Relations

    [email protected]



    Primary Logo

    Get the next $AXNX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AXNX
    $KMTS
    $NSPR
    $RXST

    CompanyDatePrice TargetRatingAnalyst
    RxSight Inc.
    $RXST
    7/15/2025$9.00Overweight → Equal-Weight
    Morgan Stanley
    RxSight Inc.
    $RXST
    7/10/2025$9.00Buy → Hold
    Jefferies
    RxSight Inc.
    $RXST
    7/9/2025Outperform → Perform
    Oppenheimer
    RxSight Inc.
    $RXST
    7/9/2025$9.00Overweight → Equal Weight
    Wells Fargo
    RxSight Inc.
    $RXST
    7/9/2025Buy → Neutral
    BTIG Research
    RxSight Inc.
    $RXST
    5/19/2025$25.00Equal Weight → Overweight
    Wells Fargo
    RxSight Inc.
    $RXST
    4/15/2025$18.00Neutral
    Piper Sandler
    RxSight Inc.
    $RXST
    4/9/2025$16.00Buy → Neutral
    UBS
    More analyst ratings

    $AXNX
    $KMTS
    $NSPR
    $RXST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    MIAMI, Sept. 25, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ: NSPR) ("InspireMD" or the "Company"), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to five (5) new non-executive employees in the aggregate amount of 88,324 shares of restricted stock (the "Inducement Grants") outside of InspireMD's 2021 Equity Incentive Plan, with a grant date as of September 24, 2025, as an inducement material to the non-executive employees entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants were gra

    9/25/25 4:05:00 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Kestra Showcases Cardiac Recovery System Platform at HFSA 2025, Redefining Sudden Cardiac Arrest Risk Management

    KIRKLAND, Wash., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ: KMTS), a wearable medical device and digital healthcare company, today announced its debut at the 2025 Heart Failure Society of America (HFSA) Annual Scientific Meeting, September 26–29 in Minneapolis, Minnesota. At booth #920, Kestra will feature its Cardiac Recovery System® (CRS) platform, anchored by the ASSURE® Wearable Cardioverter Defibrillator. The CRS platform closes the critical gap in sudden cardiac death protection by pairing protection with actionable insights that support confident care during the high-risk early phase of heart failure recovery. Attendees can explore the CRS platfo

    9/25/25 8:00:00 AM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    InspireMD Announces the Appointment of Dan Dearen to its Board of Directors

    MIAMI, Sept. 17, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Dan Dearen to its Board of Directors. Mr. Dearen brings nearly 40 years of leadership experience in the medical device and life sciences sectors, with a proven track record of guiding MedTech companies through critical financial milestones and delivering shareholder value through execution. "We are pleased to welcome Dan to InspireMD's Board of Directors," said Marvin Slosman, Chief Executive Officer of InspireMD. "He brings extensive experience, financial expertise, and

    9/17/25 8:00:00 AM ET
    $BBNX
    $NSPR
    Medical/Dental Instruments
    Health Care

    $AXNX
    $KMTS
    $NSPR
    $RXST
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Commercial Officer Ford Alfred J Jr bought $340,000 worth of shares (20,000 units at $17.00), increasing direct ownership by 68% to 49,412 units (SEC Form 4)

    4/A - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)

    9/15/25 4:30:46 PM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    Amendment: Officer Umberger Traci S bought $229,500 worth of shares (13,500 units at $17.00), increasing direct ownership by 11% to 134,336 units (SEC Form 4)

    4/A - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)

    9/15/25 4:17:34 PM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    Director Cohen Raymond W bought $289,000 worth of shares (17,000 units at $17.00) and was granted 10,909 shares, increasing direct ownership by 215% to 40,903 units (SEC Form 4)

    4 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)

    9/8/25 5:38:22 PM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    $AXNX
    $KMTS
    $NSPR
    $RXST
    SEC Filings

    View All

    InspireMD Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - InspireMD, Inc. (0001433607) (Filer)

    9/17/25 8:00:33 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Kestra Medical Technologies Ltd.

    10-Q - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Filer)

    9/12/25 4:17:17 PM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    Kestra Medical Technologies Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Filer)

    9/11/25 4:17:04 PM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    $AXNX
    $KMTS
    $NSPR
    $RXST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Goldshleger Ilya exercised 23,445 shares at a strike of $4.27, increasing direct ownership by 55% to 65,691 units (SEC Form 4)

    4 - RxSight, Inc. (0001111485) (Issuer)

    9/26/25 4:07:58 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    New insider Dearen Danny L. claimed ownership of 58,017 shares (SEC Form 3)

    3 - InspireMD, Inc. (0001433607) (Issuer)

    9/24/25 4:00:13 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Director Kester Thomas J was granted 37,815 shares, increasing direct ownership by 9% to 458,573 units (SEC Form 4)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    9/17/25 4:20:20 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $AXNX
    $KMTS
    $NSPR
    $RXST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RxSight downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded RxSight from Overweight to Equal-Weight and set a new price target of $9.00

    7/15/25 8:39:07 AM ET
    $RXST
    Ophthalmic Goods
    Health Care

    RxSight downgraded by Jefferies with a new price target

    Jefferies downgraded RxSight from Buy to Hold and set a new price target of $9.00

    7/10/25 8:36:38 AM ET
    $RXST
    Ophthalmic Goods
    Health Care

    RxSight downgraded by Oppenheimer

    Oppenheimer downgraded RxSight from Outperform to Perform

    7/9/25 8:19:00 AM ET
    $RXST
    Ophthalmic Goods
    Health Care

    $AXNX
    $KMTS
    $NSPR
    $RXST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by InspireMD Inc.

    SC 13G - InspireMD, Inc. (0001433607) (Subject)

    12/4/24 4:31:06 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by InspireMD Inc.

    SC 13G/A - InspireMD, Inc. (0001433607) (Subject)

    11/14/24 6:35:20 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by RxSight Inc.

    SC 13G/A - RxSight, Inc. (0001111485) (Subject)

    11/14/24 5:46:12 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    $AXNX
    $KMTS
    $NSPR
    $RXST
    Financials

    Live finance-specific insights

    View All

    Kestra Medical Technologies Reports First Quarter Fiscal 2026 Financial Results

    KIRKLAND, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, today reported financial results for the first quarter fiscal 2026, which ended July 31, 2025. Financial Highlights Generated revenue of $19.4 million in Q1 FY26, an increase of 52% compared to the prior year period.Expanded gross margin to 45.7% in Q1 FY26 compared to 32.9% in the prior year period.Increased FY26 revenue guidance to $88 million, representing growth of 47% compared to FY25. "We had a strong start to fiscal 2026, with our sustained commercial momentum generating revenue growth of over 50% in the first quarter," sai

    9/11/25 4:01:00 PM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    Kestra Medical Technologies, Ltd. to Report First Quarter Fiscal 2026 Financial Results

    KIRKLAND, Wash., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, today announced that it will report first quarter fiscal 2026 financial results on Thursday, September 11. Management will host a corresponding conference call at 4:30 p.m. Eastern Time. A live and archived webcast of the conference call will be available in the "Events" section of the investor relations website. Participants are encouraged to register on the website at least 10 minutes prior to the start of the conference call. About KestraKestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital h

    8/28/25 8:00:00 AM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    RxSight, Inc. Reports Second Quarter 2025 Financial Results

    ALISO VIEJO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended June 30, 2025. Key Company Highlights Reported second quarter 2025 revenue of $33.6 million, representing a decrease of 4% compared to the second quarter of 2024, reflecting: The sale of 27,380 Light Adjustable Lenses (LAL®/LAL+®), representing a 13% increase in procedure volume compared to the second quarter of 2024;The sale of 40 Light Delivery Devices (LDD™s), representing a 49% decrease compared to the sec

    8/7/25 4:05:00 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    $AXNX
    $KMTS
    $NSPR
    $RXST
    Leadership Updates

    Live Leadership Updates

    View All

    InspireMD Announces the Appointment of Dan Dearen to its Board of Directors

    MIAMI, Sept. 17, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Dan Dearen to its Board of Directors. Mr. Dearen brings nearly 40 years of leadership experience in the medical device and life sciences sectors, with a proven track record of guiding MedTech companies through critical financial milestones and delivering shareholder value through execution. "We are pleased to welcome Dan to InspireMD's Board of Directors," said Marvin Slosman, Chief Executive Officer of InspireMD. "He brings extensive experience, financial expertise, and

    9/17/25 8:00:00 AM ET
    $BBNX
    $NSPR
    Medical/Dental Instruments
    Health Care

    Kestra Medical Technologies Appoints Dr. Elizabeth Kwo to Board of Directors

    KIRKLAND, Wash., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, today announced the appointment of Elizabeth Kwo, M.D. as an independent director to its board following her election at the company's annual general meeting of shareholders held earlier this month. "I am pleased to welcome Dr. Kwo to the Kestra board of directors," said Brian Webster, President and CEO of Kestra Medical Technologies. "As a physician, healthcare executive, and entrepreneur, she brings extensive experience building and scaling digital health platforms and advancing data-driven care models to improve patient outcomes.

    9/17/25 8:00:00 AM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors

    MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Raymond W. Cohen to its Board of Directors. Mr. Cohen has over 40 years of leadership experience in medical technology with a successful track record of scaling commercial operations and creating shareholder value through market leadership and successful exit transactions. "We are thrilled to welcome Ray to InspireMD's Board of Directors," said Marvin Slosman, Chief Executive Officer of InspireMD. "We expect to benefit greatly from his vast insights and experience. His

    7/31/25 8:31:00 AM ET
    $KMTS
    $NSPR
    Medical/Dental Instruments
    Health Care